Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-09

Clinical Trial Update: Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment. [Phase 4]

View source ↗

Summary

Phase 4 trial investigating telbivudine for renal function improvement in HBsAg-positive kidney transplant recipients; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tyzeka (telbivudine)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: HBsAg-positive Renal Allograft Recipients | Phase 4 | Status: TERMINATED